Marinus Pharmaceuticals, Inc.

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.17 ^USD	-4.88%		-12.03%	-89.24%

06-24	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-17	Sector Update: Health Care Stocks Decline Premarket Monday	MT

Marinus Pharmaceuticals, Inc. Announces Management Changes

August 08, 2019 at 12:30 pm

Marinus Pharmaceuticals, Inc. appointed Scott Braunstein, MD, as CEO. Dr. Braunstein has served on the Company's Board since September 2018 and was appointed executive chairman of Marinus in February 2019. Appointed Nicole Vitullo as chairman of the board.

Ms. Vitullo has served on the Company's Board since 2005.

Latest news about Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index	06-23	CI
Sector Update: Health Care Stocks Decline Premarket Monday	06-17	MT
Top Premarket Decliners	06-17	MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study	06-17	MT
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus	06-17	CI
Marinus Pharmaceuticals, Inc. Enter into an Amendment to Its Previously Disclosed Credit Agreement with Oaktree Fund Administration, Llc	06-06	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	05-17	MT
Sector Update: Health Care	05-17	MT
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent	05-17	MT
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program	05-17	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	05-08	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	05-08	CI
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	05-07	MT
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	04-17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	04-16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	04-16	MT
North American Morning Briefing : Powell Comments, -2-	04-16	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	04-15	MT
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	04-15	MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	04-15	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index	03-17	CI
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency	03-07	MT
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder	03-07	MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	03-06	MT

Chart Marinus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Marinus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.17 USD

Average target price

6.667 USD

Spread / Average Target

+469.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MARINUS PHARMACEUTICALS, INC.	-89.24%	64.27M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals